15	*Longimycelium tulufanense*	ERKTLDKLDRKKIETRAKQVISKLAQDGDLRRELPRRTTT GHAHEEVRGVLAKSRGALHEIHGAATTVAMPLATVAWVED MARVFREKNATTLDKAATVSEIVPVAGQVLGMADGIAHRD AETVAVNAVVLAAIAVSQAVPVVGELVDLGLTAYAVVDVV VRLFGPAREVPITQESYW	WP_189053160.1 E249-W426
16	*Austwickia sp. TVS 96-490-7B* (CT3-T)	LSNIKWERVRQKSEELIKKLKDDENVKKAVQERKEGVKPT SDDLQNLHKALIDHESFKELKSVHSNGVKAMDAANAALWG ANVARVFSDSKSDGLEKATAALAAVPGLGQVMGVADGVTH HNTEEVVVQSVALAGFIAAQAIPVVGEIVDIGVLAYQFVE GVIDLSRQMMTSNAR	WP_219106995.1 L233-R407
17	*Austwickia chelonae LK16-18* (CT2-T)	LSKVKWEQVREKSKKIIDNVKDNPEFMKKLSAHHERGSAP TTEKITALHNELLDHESFSALKGARSSAGTAATAASAAAW GLAVAQAFTNPKADDLTKATAVLSAVPGLGQALGIADGIK HHNTEEIVVQSISLTALIAAQAIPVVGELVDFGLLAYQLV ESIIDLTRQLSVITAN	WP_162873017.1
36	*Klebsiella aerogenes*	GLNWGSIREKAVDKAKSVTSDKKFINSLPERGKNSPANKN DINTIYESSANHSTLKGGSEVIHKASLLLWVANTADVLTS NSSSTLDKATAIIGIVPGIGDAFSLADSIEHDDVEGIITS SIALAAFTVAQAVPVVGELVDLALLTEAAISSLVNVISNY IQSTQR	EIZ2913133.1 G211-R376
37	*Streptomyces sp. MUM 178J*	ADLDWEKVRSRAKETARQVAQDSEHVSGLPERRAEGLTKS EAHAVAERTHAKVSEVSGTRVAATAFGVGTWAYGMAQTFT DQNATTLDKVAVTTAIVPGVGNALGIADGIEHHDPEAVAV NAVALAALVAAQAVPVVGELVDTVLLTEQIVETFVNIFQR ATAA	MCH0551590.1 A229-A392
38	*Crossiella cryophila*	ETADSLGELFHQGMTIAGEAVAELDLEEALKSQKVAKGDA RAVVAGKVAAVGKQVGKSSALAKFKEVLKPSKGVIALWAV SALYTLAQEDVSTVDKAEAVLAIVPILGPLFSFGNSYRKE DVEGMVISTVALAATLIAFLCPPVGAGIGVGLAVYQVVRA FC	MBB4677777.1 E56-C217
39	*Allokutzneria sp. NRRL B-24872*	SLVKGKTDAQAVSAVKQLFENSKTVATSLVADSDMADAIK DAKKAAKVGVAPPVDKVKKVTDPLVEKALKSKSFANTKAG KYLKNAQPSKAGTALWAATTVATFLDGSSSASDKAVAAVG IIPVVGQLASLIHTTIKDPSDVEGIVTGTIGLAAAVITIA C	WP_143261759.1 S60-C220
40	*Allokutzneria albata*	KAIGATRESARKFVANILSKSEKATTTLAASNDYKSSMKGF SESFAKLRKAAAETKKPIPTADIKKLLTPHLDKVSTVKDFK KYFTNLKPSQGSAATWLVNLAATVANEESSKADVAVAAAGI IPVVGQVAAIANSVSQGDVEGTVTSAIALAANIAIAVGAG	WP_156051914.1 K78-G240
41	*Streptomyces sp. AV19*	CDIGVRDHAEVARKHQERLRAHGDDVEYVTTLDEFEKNPK SLLSPLRETNGVLNDAAAAELGAKDFEAFSTRVTEALGRD LRAVHGLSTDTTLLAKVARQAGRAAELGAKALPYVGIAAT GYAIAEDVKAGDYANLAFDSVAEGLQVAMVAQPELVPLLE PVLFAEQLAQIVYDEIAGWFKRQEQLDHDRKQWDSAAEDL	WP_199893204.1 C260-P481

CLAIMS

1. A recombinant polypeptide of general formula (I):

A-B-C (i)

in which:

A is a cargo molecule;

B is a translocation polypeptide comprising:

(a) a translocation domain from:

(i) the *Austwickia chelonae* protein of SEQ ID NO: 2;

(ii) the *Streptomyces sp.TLI 053* protein of GenBank Accession SDT83331.1;

(iii) the *Streptomyces klenkii* protein of GenBank Accession WP_120757473.1;

(iv) the *Austwickia sp. TVS 96-490-7B* protein of GenBank Accession WP_219106995.1;

(v) the *Austwickia chelonae LK16-18* protein of GenBank Accession WP_162873017.1; or

(b) a translocation domain that is at least 80% identical to the translocation domain defined in (a); and

C is a targeting moiety.

2. A recombinant polypeptide according to Claim 1, in which the translocation polypeptide comprises:

(a) the translocation domain from the *Austwickia chelonae* protein, in which the translocation domain has the amino acid sequence of SEQ ID NO: 3; or

(b) a translocation domain that is at least 80% identical to the translocation domain defined in (a).

3. A recombinant polypeptide according to Claim 1 or 2, in which the translocation polypeptide comprises:

(a) the translocation domain from the *Austwickia chelonae LK16-18* protein of GenBank Accession WP_162873017.1, in which the translocation domain has the amino acid sequence of SEQ ID NO: 17; or

(b) a translocation domain that is at least 80% identical to the translocation domain defined in (a).

4. A recombinant polypeptide according to Claim 1, 2 or 3, in which the translocation domain is as defined in (b) and is at least at least 95% identical to the translocation domain defined in (a) across the full length thereof.

5. A recombinant polypeptide according to any preceding claim, in which the translocation polypeptide is as defined in (a).

6. A recombinant polypeptide according to any preceding claim, in which A and B are separated by an amino acid linker,

preferably in which the amino acid linker comprises $(G_4S)_2$,

more preferably in which the amino acid linker is cleavable,

more preferably in which the amino acid linker comprises a protease recognition site,

more preferably in which the protease recognition site is bracketed by cysteine residues,

more preferably in which the protease recognition site is a furin protease recognition site,

more preferably in which the amino acid linker comprises SEQ ID NO: 32, which comprises the furin protease recognition site,

more preferably in which the $(G_4S)_2$ is positioned N-terminally with respect to the SEQ ID NO: 32.

7. A recombinant polypeptide according to any preceding claim, in which B and C are separated by an amino acid linker,

preferably in which the amino acid linker comprises SEQ ID NO: 33,

more preferably in which the $(G_4S)_2$ is positioned N-terminally with respect to the SEQ ID NO: 33.

8. A recombinant polypeptide according to any preceding claim, in which the targeting moiety comprises a targeting polypeptide or aptamer,

preferably in which the targeting polypeptide comprises an antibody, a binding fragment of an antibody, an affibody, a peptide, an affitin, a DARPin, or a receptor ligand,

more preferably in which the receptor ligand for αvβ6 integrin comprises the amino acid sequence of SEQ ID NO: 20.

9. A recombinant polypeptide according to Claim 8, in which the targeting moiety comprises at least two targeting polypeptides, at least two aptamers, or a combination of a targeting polypeptide and an aptamer.

10. A recombinant polypeptide according to any preceding claim, in which the targeting moiety binds to a cell surface protein,

preferably in which the cell surface protein is expressed in a disease cell,

more preferably in which the disease cell is a cancer cell.

11. A recombinant polypeptide according to any preceding claim, in which the cargo molecule comprises a therapeutic polypeptide,

preferably in which the therapeutic polypeptide comprises a cytotoxic polypeptide,

more preferably a polypeptide toxin or a functional fragment thereof.

12. A recombinant polypeptide according to Claim 11, in which the cytotoxic polypeptide comprises a catalytic domain from a Chelona Toxin,

preferably in which the catalytic domain is from:

the Chelona Toxin set forth in SEQ ID NO: 2 (CT1);

the Chelona Toxin set forth in SEQ ID NO: 21 (CT2); or

the Chelona Toxin set forth in SEQ ID NO: 35 (CT3).

13. A recombinant polypeptide according to Claim 12,

in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 2 (CT1) has the amino acid sequence according to amino acid positions 1 to 186 of SEQ ID NO: 2;

in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 21 (CT2) has the amino acid sequence according to amino acid positions 1 to 186 of SEQ ID NO: 21; or

in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 35 (CT3) has the amino acid sequence according to amino acid positions 1 to 191 of SEQ ID NO: 35.

14. A pharmaceutical composition comprising a recombinant polypeptide according to any preceding claim, together with a pharmaceutically acceptable excipient, diluent, or carrier.

15. A recombinant polypeptide according to any preceding claim for use in the treatment of cancer in a subject.